Showing 741 - 760 results of 810 for search '"Peking University"', query time: 0.08s Refine Results
  1. 741
  2. 742
  3. 743

    Predictors and Prognostic Effects of Perioperative Myocardial Injury After Transcatheter Aortic Valve Replacement According to VARC-3 Criteria by Hu X, Zhao Z, Wang C, Feng D, Chen Y, Niu G, Zhou Z, Zhang H, Li Z, Ye Y, Wang M, Wu Y

    Published 2025-02-01
    “…Xiangming Hu,1,* Zhenyan Zhao,1,* Can Wang,1,* Dejing Feng,1 Yang Chen,2 Guannan Niu,1 Zheng Zhou,1 Hongliang Zhang,1 Zhe Li,1 Yunqing Ye,1 Moyang Wang,1 Yongjian Wu1 1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Cardiology, Peking University People’s Hospital, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Moyang Wang; Yongjian Wu, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People’s Republic of China, Email wangmoyang1983@vip.sina.com; fuwaiwyj@163.comPurpose: The impact of periprocedural myocardial injury (PPMI) according to VARC-3 criteria in patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear. …”
    Get full text
    Article
  4. 744
  5. 745
  6. 746
  7. 747
  8. 748
  9. 749
  10. 750
  11. 751
  12. 752
  13. 753

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  14. 754
  15. 755
  16. 756
  17. 757
  18. 758
  19. 759
  20. 760